SELECT-AXIS 2 subgroup analysis. UPA demonstrated improved efficacy vs PBO at Wk 14 across all evaluated subgroups of pts with bDMARD-IR AS. No new safety signals. @XBaraliakos et al, Abs 0414 #ACR22 https://t.co/lTfm68XlEY https://t.co/PaWdrOljMO

• Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis wit…

Abs 0419 SELECT-AXIS 2, UPA improved outcomes vs PBO in nr-axSpA pts across all BL inflammation subgroups; greatest benefit obs in pts with both elevated CRP and inflammation on baseline MRI. #ACR22 @RheumNow https://t.co/opaFwXgcvU https://t.co/o27ULcL8Ip

• Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthri…

2022 ASAS-EULAR Recommendations of AxSpA management 1) NSAIDs still first line 2) Analgesics/opioids contraindicated 3) TNFi, IL-17i first line bDMARDs, followed by JAKinibs 4) Tapering but not discontinuation of bDMARDs in sustained remission Abs#0542 @RheumNow #ACR22 https://t.co/ffaN2fMc3v

Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA and AS patients. Factors associated with MACE/VTE: age>65, HTN, DM, smoking, history CV event/VTE Abs#0510 @RheumNow #ACR22 https://t.co/AjtJF0p3QK

Key points in managing MDA5+ DM 1. Consider Tofacitinib 5-10mg bd 2. Low to mid dose Prednisolone 20-30mg tapering 3. Other Rx: Tacrolimus, IVIG 4. Poor prognostic factors: lymphopenia, raised ferritin, old age, rapid ILD progression Wang GC, IIM session @RheumNow #ACR22 https://t.co/UF2PjAg0Mw

Therapies for AS and nr-AxSpA are coming together. Both AS and nr-AxSpA present with similar burden of disease. TNFi, IL-17i and JAKi now approved for use in nr-AxSpA. Jose U Scher, SpA Review @RheumNow #ACR22 https://t.co/vcHcd7OyAU

What do you do if a person with #rheumatoidarthritis was great on 1st JAKi. It was 1st line advanced Rx @RheumNow #ACR22